24 January 2022 - Vaxneuvance (pneumococcal 15 valent conjugate vaccine (CRM197 protein)) was approved on 17 January 2022 for active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F) in adults 18 years of age and older.

Vaxneuvance will remain in the Black Triangle Scheme for 5 years.

Read TGA Prescription Medicine Decision Summary for Vaxneuvance